<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Mol. Biol</journal-id>
<journal-id journal-id-type="publisher-id">gmb</journal-id>
<journal-title-group>
<journal-title>Genetics and Molecular Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1415-4757</issn>
<issn pub-type="epub">1678-4685</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Genética</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27575431</article-id>
<article-id pub-id-type="pmc">5004840</article-id>
<article-id pub-id-type="doi">10.1590/1678-4685-GMB-2016-0019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Series of Articles - 60 Years of The Brazilian Society of Genetics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuromuscular disorders: genes, genetic counseling and therapeutic trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zatz</surname>
<given-names>Mayana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Passos-Bueno</surname>
<given-names>Maria Rita</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vainzof</surname>
<given-names>Mariz</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label>Human Genome and Research Center (HUG-CELL), Instituto de
Biociências, Universidade de São Paulo (USP), São Paulo, SP, Brazil.</aff>
</contrib-group>
<author-notes>
<corresp id="c1">Send correspondence to Mayana Zatz. Instituto de Biociências,
Universidade de São Paulo, Rua do Matão, 106, Cidade Universitária, 05508-090, São
Paulo, Brazil. E-mail: <email>mayazatz@usp.br</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Jul-Sep</season>
<year>2016</year>
</pub-date>
<volume>39</volume>
<issue>3</issue>
<fpage>339</fpage>
<lpage>348</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>3</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016, Sociedade Brasileira de
Genética.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>License information: This is an open-access article distributed under the
terms of the Creative Commons Attribution License (type CC-BY), which permits
unrestricted use, distribution and reproduction in any medium, provided the
original article is properly cited.</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<p>Neuromuscular disorders (NMD) are a heterogeneous group of genetic conditions, with
autosomal dominant, recessive, or X-linked inheritance. They are characterized by
progressive muscle degeneration and weakness. Here, we are presenting our major
contributions to the field during the past 30 years. We have mapped and identified
several novel genes responsible for NMD. Genotype-phenotype correlations studies
enhanced our comprehension on the effect of gene mutations on related proteins and
their impact on clinical findings. The search for modifier factors allowed the
identification of a novel "protective"; variant which may have important implication
on therapeutic developments. Molecular diagnosis was introduced in the 1980s and new
technologies have been incorporated since then. Next generation sequencing greatly
improved our capacity to identify disease-causing mutations with important benefits
for research and prevention through genetic counseling of patients' families. Stem
cells researches, from and for patients, have been used as tools to study human
genetic diseases mechanisms and for therapies development. The clinical effect of
preclinical trials in mice and canine models for muscular dystrophies are under
investigation. Finally, the integration of our researches and genetic services with
our post-graduation program resulted in a significant output of new geneticists,
spreading out this expertise to our large country.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>genetic diseases</kwd>
<kwd>genetic counseling</kwd>
<kwd>neuromuscular disorders</kwd>
<kwd>stem cells</kwd>
<kwd>therapies</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="94"></ref-count>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Neuromuscular disorders (NMD) include a wide group of genetic conditions that affect
about 1 in 1000 individuals worldwide. They are characterized by progressive muscle
degeneration and weakness due to genetic mutations which primarily or secondarily impair
skeletal muscle function. Most of these mutations display autosomal recessive, autosomal
dominant or X-linked inheritance. The onset can occur in childhood and have a severe
progression or later in life with a slower course. A complete list of
diseases/genes/phenotypes is available at <ext-link ext-link-type="uri" xlink:href="http://www.musclegenetable.fr/">http://www.musclegenetable.fr/</ext-link>.</p>
<p>Our group, at the Institute of Biosciences, at the University of São Paulo, was pioneer
in establishing a center for diagnosis, genetic counseling and research in neuromuscular
disorders in the late 1970s. In the 1980s, we founded the Brazilian Muscular Dystrophy
Association, which has recently joined with a larger entity for handicapped patients,
the AACD. In 2000, the Human Genome Research Center was founded, and in 2005 stem cells
research was introduced, to the now called Human Genome and Stem Cells Research Center
(HUG-CELL). To date, we have attended about 26,000 patients with NMD and at-risk
relatives at the HUG-CELL. Here, we will summarize our main contributions to the
field.</p>
</sec>
<sec>
<title>Mapping and identification of new genes</title>
<p>Although the human genome project was declared completed in 2003, it has been recently
estimated that only 50% of the 7.315 Mendelian phenotypes, usually represented by rare
disorders, have been associated to given genes (<xref ref-type="bibr" rid="B8">Chong
<italic>et al.</italic>, 2015</xref>). This scenario is even more complex and
challenging for disorders with multifactorial inheritance, in which multiple variants,
genes, environmental effects and epigenetic phenomena may be involved and are usually
highly heterogeneous. Therefore, the identification of putative causative variants of
clinical phenotypes is still an important approach in human genetics, providing a direct
link between a particular phenotype and a given gene.</p>
<p>We have mapped 8 loci responsible for neuromuscular disorders and identified for the
first time five of their mutational gene mechanisms. We have also collaborated with the
identification of another five genes.</p>
<p>Large families with many affected members, as well as isolates with high degree of
consanguinity were very important to identify new disease genes (<xref ref-type="bibr" rid="B16">Figueiredo <italic>et al.</italic>, 2015</xref>).</p>
<sec>
<title>Duchenne Muscular Dystrophy</title>
<p>In 1981, we described a case of a girl affected by Duchenne muscular dystrophy (DMD),
carrying an X-autosomal translocation with a breakpoint at Xp21 (<xref ref-type="bibr" rid="B88">Zatz <italic>et al.</italic>, 1981</xref>). This case,
together with similar cases reported in the literature, was key to confirm the
mapping of the Duchenne locus at Xp21, leading to the identification of the DMD gene
in 1988 by the group of Louis M. Kunkel (<xref ref-type="bibr" rid="B20">Koenig
<italic>et al.</italic>, 1998</xref>; <xref ref-type="bibr" rid="B29">Monaco
<italic>et al.</italic>, 1988</xref>).</p>
</sec>
<sec>
<title>Limb-girdle muscular dystrophies</title>
<p>Subsequently we focused on limb-girdle muscular dystrophies (LGMD), a group of
disorders that affect primarily the pelvic and scapular limb-girdles. LGMD can be
transmitted through autosomal recessive (AR) and, less frequently, autosomal dominant
(AD) inheritance. Currently there are 19 AR (LGMD2A-2T) and eight AD genes
(LGMD1A-1H) already identified. Affected patients can have a mild disease course
remaining ambulant until late in life or have a severe phenotype, clinically very
similar to X-linked DMD. Among the severe forms, LGMD2C, LGMD2D, LGMD2E and LGMD2F
are sarcoglycanopathies, caused by mutations in the SGCG, SGCA, SGCB and SGCD genes,
coding for γ-SG, α-SG, β-SG, and δ-SG, components of the sarcoglycan (SG) complex.
These transmembrane glycoproteins, together with sarcospan, dystrophin,
dystroglycans, syntrophins and α-dystrobrevin, constitute the Dystrophin-glycoprotein
complex. This complex acts as a linker between the cytoskeleton of the muscle cell
and the extracellular matrix, providing mechanical support to the plasma membrane
during myofiber contraction (<xref ref-type="bibr" rid="B85">Yoshida and Ozawa,
1990</xref>). Among patients diagnosed with AR LGMD (through DNA and/or muscle
protein analysis) from 120 families in Brazil, the LGMD2A is the most frequent form
of sarcoglycanophaty (<xref ref-type="bibr" rid="B90">Zatz <italic>et al.</italic>,
2003</xref>).</p>
<p>The first LGMD gene identified by our group is responsible for LGMD2F, caused by
mutations in δ-SG gene coding for one of the four sarcoglycan proteins. This gene
causes a severe childhood form of muscular dystrophy (<xref ref-type="bibr" rid="B34">Nigro <italic>et al.</italic>, 1996</xref>; <xref ref-type="bibr" rid="B41">Passos-Bueno <italic>et al.</italic>, 1996</xref>). Another gene mapped and
identified by our group is responsible for AR-LGMD2G, caused by a mutation in the
TCAP gene, coding for the protein telethonin (<xref ref-type="bibr" rid="B30">Moreira
<italic>et al.</italic>, 1997</xref>, <xref ref-type="bibr" rid="B31">2000</xref>). Although identified in compound heterozygous patients belonging to
a family of Italian origin, LGMD2G has been shown afterwards to be very rare, and few
cases have been reported outside Brazil. LGMD2G is characterized by a variable
phenotype, with onset in childhood or adulthood (<xref ref-type="bibr" rid="B72">Vainzof <italic>et al.</italic>, 2002</xref>).</p>
<p>The protein telethonin is a 19 kDa component of the sarcomere Z-disk in striated and
cardiac muscles (<xref ref-type="bibr" rid="B77">Valle <italic>et al.</italic>,
1997</xref>). Telethonin is the first example of a sarcomeric protein, of which
deficiency was associated with a form of muscular dystrophy, without disruption of
the sarcomere structure (<xref ref-type="bibr" rid="B72">Vainzof <italic>et
al.</italic>, 2002</xref>).</p>
<p>More recently we have identified the gene for the AD LGMD1G muscular dystrophy (<xref ref-type="bibr" rid="B81">Vieira <italic>et al.</italic>, 2014</xref>), which had
been mapped by our group 10 years earlier (<xref ref-type="bibr" rid="B58">Starling
<italic>et al.</italic>, 2004</xref>). Mutations in the RNA-processing protein
HNRPDL, a heterogeneous ribonucleoprotein family member, which participates in mRNA
biogenesis and metabolism, were identified in two large, unrelated families: one from
Brazil and the other from Uruguay. The identification of the LGMD1G gene revealed a
novel association between a muscular disorder and an RNA-related gene and reinforces
the importance of RNA binding/processing proteins in muscle development and muscle
disease.</p>
<p>We also collaborated in the identification of LGMD2A (<xref ref-type="bibr" rid="B3">Beckmann <italic>et al.</italic>, 1991</xref>; <xref ref-type="bibr" rid="B44">Richard <italic>et al.</italic>, 1995</xref>; <xref ref-type="bibr" rid="B54">Spencer <italic>et al.</italic>, 1997</xref>), LGMD2B (<xref ref-type="bibr" rid="B40">Passos-Bueno <italic>et al.</italic>, 1995</xref>; <xref ref-type="bibr" rid="B5">Bushby <italic>et al.</italic>, 1996</xref>; <xref ref-type="bibr" rid="B2">Bashir <italic>et al.</italic>, 1998</xref>;), LGMD2C (<xref ref-type="bibr" rid="B24">McNally <italic>et al.</italic>, 1996b</xref>), LGMD2D
and LGMD2E genes (<xref ref-type="bibr" rid="B4">Bonnemann <italic>et al.</italic>,
1996</xref>), responsible for several forms of AR-LGMDs (<xref ref-type="bibr" rid="B90">Zatz <italic>et al.</italic>, 2003</xref>).</p>
</sec>
<sec>
<title>Spastic paraplegia (SPG)</title>
<p>We have mapped and/or identified several genes responsible for pure spastic
paraplegia, namely SPG8 (<xref ref-type="bibr" rid="B46">Rocco <italic>et
al.</italic>, 2000</xref>; <xref ref-type="bibr" rid="B76">Valdmanis <italic>et
al.</italic>, 2007</xref>), SPG4 (<xref ref-type="bibr" rid="B56">Starling
<italic>et al.</italic>, 2002b</xref>; <xref ref-type="bibr" rid="B26">Mitne-Neto <italic>et al.</italic>, 2007a</xref>), or X-linked SPG (<xref ref-type="bibr" rid="B55">Starling <italic>et al.</italic>, 2002a</xref>). Our
group also described a new complicated autosomal recessive form of spastic paraplegia
named SPOAN (spastic paraplegia, optic atrophy, neuropathy) (<xref ref-type="bibr" rid="B21">Macedo-Souza <italic>et al.</italic>, 2005</xref>, <xref ref-type="bibr" rid="B22">2009</xref>). SPOAN was identified in a geographically isolated region
in the backlands of Northeastern Brazil, known for a high incidence of consanguineous
marriages. The mutation, recently identified through whole genome sequencing, is a
homozygous deletion in the noncoding region of the kinesin light chain-2
(<italic>KLC2</italic>) gene, a novel mechanism, which reinforces the importance
of noncoded regions in human pathology (<xref ref-type="bibr" rid="B25">Melo
<italic>et al.</italic>, 2015</xref>).</p>
</sec>
<sec>
<title>Motor neuron diseases</title>
<p>Motor neuron diseases are a group of neurodegenerative disorders with involvement of
upper and/or lower motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal
muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis. A new
locus for a recessive X-linked juvenile form of distal muscular atrophy has also been
mapped in our lab (<xref ref-type="bibr" rid="B59">Takata <italic>et al.</italic>,
2004</xref>).</p>
<p>However, a more important contribution from our group was the mapping and subsequent
identification of the amyotrophic lateral sclerosis gene 8 or ALS8 in a very large
Brazilian genealogy (<xref ref-type="bibr" rid="B35">Nishimura <italic>et
al.</italic>, 2004a</xref>,<xref ref-type="bibr" rid="B36">b</xref>). This gene
codes for the vesicle-associated membrane protein/synaptobrevin-associated membrane
protein B (<italic>VAPB</italic>) gene. Members of the vesicle-associated proteins
are intracellular membrane proteins that can associate with microtubules and that
have been shown to have a function in membrane transport (<xref ref-type="bibr" rid="B27">Mitne-Neto <italic>et al.</italic>, 2007b</xref>). We have also shown
that the <italic>VAPB</italic> mutation, which is now identified in hundreds of
Brazilian patients, is due to a founder effect (<xref ref-type="bibr" rid="B37">Nishimura <italic>et al.</italic>, 2005</xref>). <italic>VAPB</italic> mutations
have been subsequently identified in patients with different origin – from Japan and
Europe (<xref ref-type="bibr" rid="B17">Funke <italic>et al.</italic>, 2010</xref>).
This finding has attracted a lot of attention from researchers in the field because
<italic>VAPB</italic> seems to be involved in other forms of ALS (<xref ref-type="bibr" rid="B9">Coatti <italic>et al.</italic>, 2015</xref>; <xref ref-type="bibr" rid="B61">Teuling <italic>et al.</italic>, 2007</xref>).</p>
</sec>
</sec>
<sec>
<title>Genotype-phenotype correlations</title>
<p>Neuromuscular disorders are characterized by marked phenotypic and genotypic
heterogeneity, with a similar clinical course caused by mutations in different genes
while several different phenotypes can be associated with mutations in one particular
gene (<xref ref-type="bibr" rid="B89">Zatz <italic>et al.</italic>, 2000</xref>). Our
group has contributed with this characterization for several forms of muscular
dystrophies.</p>
<p>After the identification of the dystrophin gene as the protein involved in DMD, a
correlation between dystrophin presence/quantity and the severity of the phenotype in
dystrophinopathies was strongly suggested. Genotype, phenotype and protein analysis
enabled us to pinpoint the important functional domains of the dystrophin protein (<xref ref-type="bibr" rid="B67">Vainzof <italic>et al.</italic>, 1993</xref>; <xref ref-type="bibr" rid="B39">Passos-Bueno <italic>et al.</italic>, 1994</xref>), and
question the previously suggested correlation (<xref ref-type="bibr" rid="B63">Vainzof
<italic>et al.</italic>, 1990</xref>, <xref ref-type="bibr" rid="B65">1991b</xref>, <xref ref-type="bibr" rid="B66">c</xref>, <xref ref-type="bibr" rid="B69">1995b</xref>).</p>
<p>For most forms of autosomal recessive LGMDs, missense mutations, on average, have been
associated with a milder phenotype as compared to null mutations. (<xref ref-type="bibr" rid="B45">Richard <italic>et al.</italic>, 1999</xref>; <xref ref-type="bibr" rid="B12">de Paula <italic>et al.</italic>, 2002</xref>; <xref ref-type="bibr" rid="B57">Starling <italic>et al.</italic>, 2003</xref>). We also observed that
mutations in the LGMD2I genes, first reported in severe congenital forms, could be also
found in adult forms with slow progression or even asymptomatic cases (<xref ref-type="bibr" rid="B13">de Paula <italic>et al.</italic>, 2003</xref>), associated
with specific protein alterations in the muscle (<xref ref-type="bibr" rid="B84">Yamamoto <italic>et al.</italic>, 2008</xref>). Muscle protein characterizations
have contributed to elucidate the organization of the dystrophin-glycoprotein complex
(<xref ref-type="bibr" rid="B64">Vainzof <italic>et al.</italic>, 1991a</xref>, <xref ref-type="bibr" rid="B70">1996</xref>, <xref ref-type="bibr" rid="B71">1999</xref>),
for genotype-phenotype correlation studies and had an important role in NMD diagnosis.
After the introduction of next generation sequencing (NGS), molecular diagnosis is
achieved directly with DNA analysis and therefore muscle biopsies have been obtained
only for research purposes.</p>
</sec>
<sec>
<title>The search for modifier (protective) variants/factors</title>
<p>Genotype-phenotype correlation studies revealed that, for several disorders such as
LGMD, facioscapulohumeral muscular dystrophy, the same disease mutation usually
associated with a severe phenotype could be also found in individuals only mildly
affected or even asymptomatic (<xref ref-type="bibr" rid="B4">Bonnemann <italic>et
al.</italic>, 1996</xref>; <xref ref-type="bibr" rid="B12">de Paula <italic>et
al.</italic>, 2002</xref>, <xref ref-type="bibr" rid="B13">2003</xref>; <xref ref-type="bibr" rid="B23">McNally <italic>et al.</italic>, 1996a</xref>; <xref ref-type="bibr" rid="B32">Moreira <italic>et al.</italic>, 2003</xref>; <xref ref-type="bibr" rid="B57">Starling <italic>et al.</italic>, 2003</xref>; <xref ref-type="bibr" rid="B62">Tonini <italic>et al.</italic>, 2004</xref>; <xref ref-type="bibr" rid="B43">Ricci <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B49">Scionti <italic>et al.</italic>, 2012</xref>). Although
rare, this has also been observed for DMD (<xref ref-type="bibr" rid="B92">Zatz
<italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B7">Castro-Gago,
2015</xref>; <xref ref-type="bibr" rid="B87">Zatz, 2015</xref>). Utrophin, an
autosomal ubiquitously expressed protein with structural homology to dystrophin, has
been suggested as a possible modulator of DMD severity and thus as a therapeutic target
for treating DMD. However, we observed that utrophin expression does not differ between
severely and mildly affected DMD patients (<xref ref-type="bibr" rid="B68">Vainzof
<italic>et al.</italic>, 1995a</xref>, <xref ref-type="bibr" rid="B74">Vainzof
2016</xref>).</p>
<p>Therefore, the search for protective variants or mechanisms continues to be a great
challenge. Interestingly, the identification of two golden retriever muscular dystrophy
(GRMD) dogs with a very mild phenotype and a normal lifespan (<xref ref-type="bibr" rid="B94">Zucconi <italic>et al.</italic>, 2010</xref>; <xref ref-type="bibr" rid="B92">Zatz <italic>et al.</italic>, 2014</xref>) have been the subject of much
investigation. We have recently shown that up-regulation of <italic>Jagged1</italic>,
which is a known regulator of the Notch pathway, is responsible for the milder course in
these two dogs (<xref ref-type="bibr" rid="B82">Vieira <italic>et al.</italic>,
2015</xref>). In addition, in the mdx mouse model for DMD, we observed a milder
course associated with less fibrosis and more regeneration when the mutation was
transferred to a different background (unpublished observations). Identifying what
protects some exceptional dogs, mice or individuals from the deleterious effect of a
disease-causing mutation is a great challenge which could open new venues for treatment
(<xref ref-type="bibr" rid="B10">Cohn and Dubowitz, 2016</xref>).</p>
</sec>
<sec>
<title>Genetic testing</title>
<p>Research in human and medical genetics allied to genetic counseling services in Brazil
initiated in the late 1960s. During those years, the model implemented by Oswaldo
Frota-Pessoa in our Department consisted of research associated with services to
patients and families, in a mutually beneficial scenario: patients contributed to new
findings, while those new findings helped patients. This model has been maintained by
the geneticists at the Human Genome and Stem Cells Research Center. Genetic testing and
genetic counseling in our community, has been one of the main activities of HUG-CELL
with emphasis to the group of disorders associated with research projects, including:
neuromuscular, neurodegenerative, craniofacial, deafness, intellectual disability, and
Autism Spectrum disorders.</p>
<sec>
<title>From Southern blot to next generation sequencing</title>
<p>Molecular diagnosis for neuromuscular disorders was introduced in our center in the
late 1980s based on Southern blot and PCR (polymerase chain reaction) analysis. The
introduction of these methods have largely contributed for the development of
research as well as for the prevention of new cases, based on diagnosis of NMD
families, carrier detection in DMD/DMB families and genetic counseling. The detection
of deletions in the dystrophin gene (which account for 60–70% of the mutations
responsible for Duchenne dystrophy) were first performed by Southern blot, followed
by multiplex analysis of the most common deleted exons by PCR. In the 1990's, the use
of microsatellite markers throughout the genome led to the mapping of novel NMD
genes. In addition, microsatellite markers within and flanking the dystrophin gene,
allowed us to improve DMD/DMB carriers detection tests by segregation analysis,
particularly in familial cases in which no deletion had been detected in the
dystrophin gene. In the mid 1990's, genetic testing for diagnosis of Myotonic
muscular dystrophy and Facioscapulohumeral disorder were introduced, both based on
Southern blot methodology. In 2000, with the inauguration of the Human Genome Center,
a non-profit DNA diagnostic lab was installed. The acquisition of a semi-automated
Sanger sequencing equipment opened the possibility to again expand and improve
genetic testing (by allowing the larger scale use of Sanger sequencing methodology)
and include other NMD, particularly the limb-girdle muscular dystrophies. This
expansion also enabled us to reach a much wider public. In addition to benefiting
patients/families seen at our center it allowed the performance of updated molecular
diagnosis in DNA samples from patients throughout Brazil. Our laboratory was also one
of the first core sequencing facilities at University of Sao Paulo, a service that
has been offered since then and which has been continuously updated. A recent new
improvement in 2013-2014 was the acquisition of next generation sequencing (NGS)
equipment (MiSeq and HiSeq, Illumina) and standardization of its methodology. NGS,
based on a panel of 80 genes, increased significantly the efficacy of NMD diagnosis,
with molecular alterations being identified in ~73% of the cases. In addition to
decreasing the cost of NMD testing, the use of a panel of genes avoids the ethical
issues associated to the identification of incidental findings through exome
sequencing. NGS has also imposed a great challenge in bioinformatics training and
expertise development on how to deal, store and analyze large data sets.</p>
<p>Whole exome sequencing (WES) which was standardized in our center in 2014 has brought
important contributions to basic research, and to identification of new disease loci
and pathogenic mutations. WES also enables a better characterization of the Brazilian
population genetic variability, which is crucial for interpreting sequence analysis
and for obtaining accurate diagnosis (<xref ref-type="bibr" rid="B91">Zatz <italic>et
al.</italic>, 2012</xref>) (<ext-link ext-link-type="uri" xlink:href="http://laboratorio.genoma.ib.usp.br">http://laboratorio.genoma.ib.usp.br</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://genoma.ib.usp.br">http://genoma.ib.usp.br</ext-link>).</p>
</sec>
</sec>
<sec>
<title>Genetic counseling</title>
<p>Genetic counseling (GC) is of upmost importance for the prevention of genetic diseases,
especially for the untreatable ones. The process of GC includes diagnosis confirmation,
identification of at-risk members, prenatal and pre-implantation diagnosis, as well as
family orientation on management of affected patients.</p>
<p>Several ethical issues regarding the use of genetic tests have been the subject of much
debate since the pre-molecular era, particularly regarding asymptomatic at-risk
relatives in late-onset disorders. In accordance with an international consensus, we do
not test asymptomatic children at-risk for late-onset disorders for which there is no
treatment, such as cerebellar ataxias or myotonic dystrophy, as this decision should be
taken solely by the subjects themselves when they reach adulthood. On the other hand,
the identification of asymptomatic carriers for recessive autosomal or X-linked diseases
can be crucial for the reproductive decisions of the parents.</p>
<p>Before offering genetic testing, several issues are discussed with patients or family
members, such as which individuals should be tested, implications of test results, and
how to deal with unexpected findings, such as false paternity.</p>
<p>More recently, the introduction of exome sequencing has opened new ethical debates
particularly related to incidental findings. What should be disclosed? What is the
geneticist's responsibility? Do patients and family members understand all the
possibilities when signing informed consents about their willingness to be informed or
not? As there is still no Brazilian regulation on this matter, we have adopted the
criteria of: <xref ref-type="bibr" rid="B1">ACMG (American College of Medical Genetics
and Genomics) Board of Directors (2013)</xref>. We provide information to those who
are interested about the at-risk variants associated with disorders, to which preventive
measures and/or treatment are available. Our experience has shown that there is no rigid
rule and each case has to be discussed by the genetic counseling team before deciding
how to better approach the patients' family.</p>
<p>Most services in Brazil offer prenatal diagnosis (PND) in spite of abortion not being
allowed for genetic disorders reasons (the only exception for a legal abortion is the
confirmation of anencephaly). In our service we decided to perform PND in the 1990s for
at-risk women, who would otherwise interrupt their pregnancy, fearing that their fetus
could be affected by a genetic disorder (for example mothers or sisters of Duchenne
muscular dystrophy patients or parents at-risk for congenital muscular dystrophy 1A,
(<xref ref-type="bibr" rid="B83">Yamamoto <italic>et al.</italic>, 2004</xref>, <xref ref-type="bibr" rid="B73">Vainzof <italic>et al.</italic>, 2005</xref>). In the
majority of cases referred for PND, the test results are negative for the mutation
present in the family, and as a result, more women are encouraged to continue their
pregnancies and unaffected babies are saved. Moreover, since many of our patients come
from a poor social background, orientation on management of the genetic disease has been
an important part of our service. This approach was the subject of a paper celebrating
125 years of Science magazine in 2005 (<xref ref-type="bibr" rid="B86">Zatz,
2005</xref>). More recently, psychoanalytical support and follow-up for patients and
at-risk relatives has also been offered in our center, which has been very important
particularly for patients with degenerative disorders. Finally, the integration of
community services with our post-graduation program results in a significant
contribution in the training of a number of geneticists, enabling them to start new
Centers in other Brazilian cities and spread out this expertise to our large
country.</p>
</sec>
<sec>
<title>Stem cells: from patients and for patients</title>
<sec>
<title>Stem cells from patients: IPSc cells</title>
<p>The groundbreaking discovery of induced pluripotent stem cells (iPSCs) by Dr.
Yamanaka's group in 2006 (<xref ref-type="bibr" rid="B60">Takahashi and Yamanaka,
2006</xref>), demonstrating the possibility to reprogram differentiated cells to
an embryonic-like stem cell, opened a new venue for research. While applications of
iPSCs in cell therapy are envisioned but still in a premature stage of development,
the use of iPSCs as tools to study human genetic diseases mechanisms boomed in the
last few years. With this in mind, we have established an IPS cells bank from
patients with different neuromuscular disorders. One interesting result was obtained
with patients affected by amyotrophic lateral sclerosis type 8 which had been
identified by our group. We have successfully reprogrammed fibroblasts from ALS8
patients and generated motor neurons. Our results suggest that optimal levels of VAPB
may play a central role in the pathogenesis of ALS8, which is in agreement with the
observed reduction of VAPB in sporadic ALS and <italic>SOD1</italic> murine model
(<xref ref-type="bibr" rid="B28">Mitne-Neto <italic>et al.</italic>,
2011</xref>).</p>
<p>The most recent gene editing CRISPR-cas9 technology (<xref ref-type="bibr" rid="B15">Doudna and Charpentier, 2014</xref>) applied to different cells derived from
IPSCs will certainly bring important contributions to functional studies, enhancing
our comprehension on pathological mechanisms underlying neuromuscular disorders and
providing new opportunities for treatment.</p>
</sec>
<sec>
<title>Stem cells for patients: cell therapy</title>
<sec>
<title>Preclinical trials in neuromuscular and neurodegenerative disorders</title>
<p>The possibility to treat progressive muscular dystrophies, particularly DMD, with
stem cell therapy has been of great interest and the focus of many investigations.
Before starting therapeutic trials, several questions need to be addressed: What
is the effect of stem-cell therapy for muscular dystrophies in animal models? What
is the best source of adult stem cells? Is immunosuppression necessary? Are the
experiments reproducible with different cell lines, or from different donors?
Should injections be local or systemic? Most importantly, what is the safety level
of non autologous stem cell transplantation? This last issue is very important for
genetic conditions such as neuromuscular disorders where autologous stem cell
transplantation is unlikely to be beneficial. In order to address these questions
we have performed a series of pre-clinical experiments with human-derived stem
cells transplanted into different murine models and GRMD dogs.</p>
<p>Comparison between different sources of stem cells revealed that cord tissue is a
much richer source of stem cells than umbilical cord blood, and that mesenchymal
stem cells from blood and tissue have a different expression profile (<xref ref-type="bibr" rid="B50">Secco <italic>et al.</italic>, 2008a</xref>,<xref ref-type="bibr" rid="B51">b</xref>, <xref ref-type="bibr" rid="B52">2009</xref>). The relevance of this observation, which resulted in a highly cited
paper, was based on the fact that umbilical cord blood banks (both public and
private) had been storing blood and discarding tissue. Next, we also identified
fallopian tubes as an important source of stem cells, with potential to enhance
bone regeneration (<xref ref-type="bibr" rid="B18">Jazedje <italic>et
al.</italic>, 2009</xref>, <xref ref-type="bibr" rid="B19">2012</xref>).</p>
<p>Several reports on stem cell transplantation have been published by other groups
in murine as well as canine models of muscular dystrophy using immunosuppressed
animals (<xref ref-type="bibr" rid="B14">Di Rocco <italic>et al.</italic>,
2006</xref>; <xref ref-type="bibr" rid="B48">Sampaolesi <italic>et
al.</italic>, 2006</xref>; <xref ref-type="bibr" rid="B47">Rouger <italic>et
al.</italic>, 2011</xref>; <xref ref-type="bibr" rid="B38">Nitahara-Kasahara
<italic>et al.</italic>, 2012</xref>). This approach may hinder the
interpretation of clinical effects of stem cell injections since immunosuppressant
drugs have a beneficial effect on muscular dystrophy (<xref ref-type="bibr" rid="B11">Davies and Grounds, 2006</xref>). Therefore, we performed our
xenotransplantation experiments without any immunosuppression therapy. We first
analyzed the effect of human adipose-derived stem cells (hASCs), which were
injected in <italic>SJL</italic> mice (the murine model for dysferlinopathy).
Human cells were well tolerated and treated mice performed significantly better
than untreated controls in functional tests (<xref ref-type="bibr" rid="B78">Vieira <italic>et al.</italic>, 2008</xref>). We next compared the effect of
human umbilical cord stem cells injected in <italic>SJL</italic> mice using the
same protocol. Differently from the experiment with hASCs, injected mice did not
show any functional improvement but untreated controls showed a decline in
functional tests (<xref ref-type="bibr" rid="B79">Vieira <italic>et al.</italic>,
2010</xref>; <xref ref-type="bibr" rid="B80">2012</xref>).</p>
<p>The next question we wanted to answer was whether observed discrepancies were due
to donors' different genetic background or different stem cell sources. Therefore,
we compared the effect of pericytes (which are precursors of mesenchymal stem
cells, <xref ref-type="bibr" rid="B6">Caplan and Sorrell, 2015</xref>) derived
from different tissues (adipose tissue, endometrium, abdominal muscle and
fallopian tube) from a female donor undergoing hysterectomy. Pericytes were
injected intraperitoneally in double-knockout mdx/utrophin mice. We observed a
beneficial effect only in pericyte-injected animals, which lived significantly
longer (~ 25%) (<xref ref-type="bibr" rid="B75">Valadares <italic>et al.</italic>,
2014</xref>).</p>
</sec>
<sec>
<title>The danger of stem cell contamination using Parkinson's disease as a
model</title>
<p>Preliminary trials to treat highly prevalent neurodegenerative diseases, such as
Parkinson's disease (PD), with mesenchymal stem cells have generated controversial
results. In a rat model of PD induced by the MPTP neurotoxin, we first observed a
significant bilateral preservation of dopaminergic neurons in the substantia nigra
and prevention of motor deficits typically observed in PD, following intracerebral
administration of human umbilical cord-derived mesenchymal stem cells (UC-MSC)
early after MPTP injury. However, surprisingly, administration of fibroblasts
-mesenchymal cells without stem cell properties, as a xenotransplantation control
was highly detrimental, causing significant neurodegeneration and motor
dysfunction independently of MPTP administration. Our pre-clinical study suggests
that fibroblasts may be common cell contaminants affecting the clinical outcome in
stem cell therapy protocols, which might also explain the discrepant clinical
results (<xref ref-type="bibr" rid="B42">Pereira <italic>et al.</italic>,
2011</xref>). These observations should be widely disseminated, since many
private clinics claim to be injecting stem cells to treat many different diseases
while, in reality, it is unknown how well characterized these injected cells
are.</p>
</sec>
<sec>
<title>Safety of nonautologous stem cell transplantation: GRMD dogs</title>
<p>To investigate the safety of nonautologous stem cell transplantation, we injected
hASCs in the best available animal model for DMD: the golden retriever muscular
dystrophy (GRMD) model. Affected animals carry a frameshift point mutation
resulting in the absence of the muscle protein dystrophin (<xref ref-type="bibr" rid="B53">Sharp <italic>et al.</italic>, 1992</xref>). These dogs have a severe
disease course and most do not survive beyond two years, despite some may have a
variable phenotype. Although no human dystrophin was found in muscles from
recipient dogs, a functional improvement was observed shortly after a series of
injections followed by an apparent stabilization afterwards, without noticeable
side effects. A growing body of evidence indicates that although mesenchymal stem
cells are partially defined by their ability to differentiate into various tissues
<italic>in vitro,</italic> it is their trophic, paracrine and immunomodulatory
functions that may have the greatest therapeutic impact <italic>in vivo</italic>,
decreasing inflammation and fibrosis (<xref ref-type="bibr" rid="B33">Murphy
<italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="B6">Caplan
and Sorrell, 2015</xref>). This would explain the beneficial effect observed in
the injected GRMD dogs. In short, we showed that repeated injections of hASCs,
from different donors, are well tolerated in immunocompetent GRMD dogs. We also
observed functional benefits in three dogs followed from four to six years
post-transplantation, without tumor formation. This study has the longest
follow-up of human cells transplanted animals ever reported. These observations,
which should be replicated in larger samples, might have important applications
for future therapy in patients with different forms of muscular dystrophies (<xref ref-type="bibr" rid="B93">Zatz <italic>et al.</italic>, 2015</xref>).</p>
</sec>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work would not have been possible without the financial support of FAPESP, CNPq,
INCT, FINEP, ABDIM/AACD, Duchenne research fund and the University of Sao Paulo. We are
extremely grateful to all students and the team at the Human Genome and stem-cell
center, and the Genedog kennel, who participated in these studies. Special thanks go to
thousands of patients and their families for their great support and encouragement, and
for showing us what is really important in life.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1">
<p>
<italic>Associate Editor: Francisco Mauro Salzano</italic>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>ACMG (American College of Medical Genetics) Board of Directors</collab>
</person-group>
<year>2013</year>
<article-title>Points to consider for informed consent for genome/exome
sequencing</article-title>
<source/>Genet Med
          <volume>15</volume>
<fpage>748</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="pmid">23970068</pub-id>
</element-citation>
</ref>
<ref id="B2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bashir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Strachan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Keers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vafiadaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lako</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Marchand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bourg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Argov</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<year>1998</year>
<article-title>A gene related to <italic>Caenorhabditis elegans</italic>
spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type
2B</article-title>
<source/>Nat Genet
          <volume>20</volume>
<fpage>37</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">9731527</pub-id>
</element-citation>
</ref>
<ref id="B3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckmann</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hillaire</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Broux</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Antignac</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bois</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cottingham</surname>
<given-names>RW</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Feingold</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Feingold</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>1991</year>
<article-title>A gene for limb-girdle muscular dystrophy maps to chromosome 15 by
linkage</article-title>
<source/>C R Acad Sci III
          <volume>312</volume>
<fpage>141</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">1901754</pub-id>
</element-citation>
</ref>
<ref id="B4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnemann</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Sa Moreira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>1996</year>
<article-title>Genomic screening for beta-sarcoglycan gene mutations: Missense
mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD
2E)</article-title>
<source/>Hum Mol Genet
          <volume>5</volume>
<fpage>1953</fpage>
<lpage>1961</lpage>
<pub-id pub-id-type="pmid">8968749</pub-id>
</element-citation>
</ref>
<ref id="B5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bushby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bashir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Keers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lovett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mahjneh</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Marconi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Strachan</surname>
<given-names>T</given-names>
</name>
</person-group>
<year>1996</year>
<article-title>The molecular biology of LGMD2B—towards the identification of the LGMD
gene on chromosome 2p13</article-title>
<source/>Neuromuscul Disord
          <volume>6</volume>
<fpage>491</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="pmid">9027860</pub-id>
</element-citation>
</ref>
<ref id="B6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caplan</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Sorrell</surname>
<given-names>JM</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>The MSC curtain that stops the immune system</article-title>
<source/>Immunol Lett
          <volume>168</volume>
<fpage>136</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="pmid">26079607</pub-id>
</element-citation>
</ref>
<ref id="B7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro-Gago</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Milder course in Duchenne patients with nonsense mutations and no
muscle dystrophin</article-title>
<source/>Neuromuscul Disord
          <volume>25</volume>
<fpage>443</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="pmid">25777491</pub-id>
</element-citation>
</ref>
<ref id="B8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Buckingham</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Jhangiani</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Boehm</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sobreira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Harrell</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>McMillin</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wiszniewski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gambin</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges,
and Opportunities</article-title>
<source/>Am J Hum Genet
          <volume>7</volume>
<fpage>199</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">26166479</pub-id>
</element-citation>
</ref>
<ref id="B9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coatti</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Beccari</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Olavio</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Okamoto</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Stem cells for amyotrophic lateral sclerosis modeling and therapy:
Myth or fact?</article-title>
<source/>Cytometry A
          <volume>87</volume>
<fpage>197</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="pmid">25645594</pub-id>
</element-citation>
</ref>
<ref id="B10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohn</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Dubowitz</surname>
<given-names>V</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Duchenne muscular dystrophy: Ringo to the rescue?</article-title>
<source/>Neuromuscul Disord
          <volume>26</volume>
<fpage>5</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">26801251</pub-id>
</element-citation>
</ref>
<ref id="B11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Grounds</surname>
<given-names>MD</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Treating muscular dystrophy with stem cells?</article-title>
<source/>Cell
          <volume>127</volume>
<fpage>1304</fpage>
<lpage>1306</lpage>
<pub-id pub-id-type="pmid">17190595</pub-id>
</element-citation>
</ref>
<ref id="B12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Paula</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>de Cassia</surname>
<given-names>MPR</given-names>
</name>
<name>
<surname>Matioli</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LVB</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2002</year>
<article-title>Clinical variability in calpainopathy: What makes the
difference?</article-title>
<source/>Eur J Hum Genet
          <volume>10</volume>
<fpage>825</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">12461690</pub-id>
</element-citation>
</ref>
<ref id="B13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Paula</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>LU</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Cassia Pavanello</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Asymptomatic carriers for homozygous novel mutations in the FKRP gene:
The other end of the spectrum</article-title>
<source/>Eur J Hum Genet
          <volume>11</volume>
<fpage>923</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="pmid">14647208</pub-id>
</element-citation>
</ref>
<ref id="B14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Rocco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Iachininoto</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Tritarelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Straino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zacheo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Germani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crea</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Capogrossi</surname>
<given-names>MC</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Myogenic potential of adipose-tissue-derived cells</article-title>
<source/>J Cell Sci
          <volume>119</volume>
<fpage>2945</fpage>
<lpage>2952</lpage>
<pub-id pub-id-type="pmid">16825428</pub-id>
</element-citation>
</ref>
<ref id="B15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Charpentier</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Genome editing. The new frontier of genome engineering with
CRISPR-Cas9</article-title>
<source/>Science
          <fpage>346</fpage>
<lpage>346</lpage>
<comment>1258096</comment>
<pub-id pub-id-type="pmid">25324387</pub-id>
</element-citation>
</ref>
<ref id="B16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueiredo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Melo</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Pessoa</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Nobrega</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Kitajima</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Homozygous missense mutation in MED25 segregates with syndromic
intellectual disability in a large consanguineous family</article-title>
<source/>J Med Genet
          <volume>52</volume>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">25527630</pub-id>
</element-citation>
</ref>
<ref id="B17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Funke</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Esser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruttgen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Lazar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sperfeld</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Trillenberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>2010</year>
<article-title>The p.P56S mutation in the VAPB gene is not due to a single founder:
The first European case</article-title>
<source/>Clin Genet
          <volume>77</volume>
<fpage>302</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">20447143</pub-id>
</element-citation>
</ref>
<ref id="B18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perin</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Czeresnia</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Maluf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Human fallopian tube: A new source of multipotent adult mesenchymal
stem cells discarded in surgical procedures</article-title>
<source/>J Transl Med
          <volume>7</volume>
<fpage>46</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">19538712</pub-id>
</element-citation>
</ref>
<ref id="B19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Almada</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Caetano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Czeresnia</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Perin</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maluf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Nisenbaum</surname>
<given-names>MG</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Human fallopian tube mesenchymal stromal cells enhance bone
regeneration in a xenotransplanted model</article-title>
<source/>Stem Cell Rev
          <volume>8</volume>
<fpage>355</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">21744049</pub-id>
</element-citation>
</ref>
<ref id="B20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Kunkel</surname>
<given-names>LM</given-names>
</name>
</person-group>
<year>1998</year>
<article-title>The complete sequence of dystrophin predicts a rod-shaped cytoskeletal
protein</article-title>
<source/>Cell
          <volume>53</volume>
<fpage>219</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">3282674</pub-id>
</element-citation>
</ref>
<ref id="B21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macedo-Souza</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lezirovitz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lino</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Spastic paraplegia, optic atrophy, and neuropathy is linked to
chromosome 11q13</article-title>
<source/>Ann Neurol
          <volume>57</volume>
<fpage>730</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="pmid">15852396</pub-id>
</element-citation>
</ref>
<ref id="B22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macedo-Souza</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Licinio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lezirovitz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cavacana</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pessoa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Graciani</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<year>2009</year>
<article-title>Spastic paraplegia, optic atrophy, and neuropathy: New observations,
locus refinement, and exclusion of candidate genes</article-title>
<source/>Ann Hum Genet
          <volume>73</volume>
<fpage>382</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="pmid">19344448</pub-id>
</element-citation>
</ref>
<ref id="B23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNally</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Duggan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gorospe</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Bonnemann</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Fanin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pegoraro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lidov</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>RS</given-names>
</name>
<etal></etal>
</person-group>
<year>1996a</year>
<article-title>Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan
cause muscular dystrophy</article-title>
<source/>Hum Mol Genet
          <volume>59</volume>
<fpage>1841</fpage>
<lpage>1847</lpage>
<pub-id pub-id-type="pmid">8923014</pub-id>
</element-citation>
</ref>
<ref id="B24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNally</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bonnemann</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Sa Moreira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lidov</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Othmane</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Denton</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>1996b</year>
<article-title>Mild and severe muscular dystrophy caused by a single
gamma-sarcoglycan mutation</article-title>
<source/>Am J Hum Genet
          <volume>59</volume>
<fpage>1040</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="pmid">8900232</pub-id>
</element-citation>
</ref>
<ref id="B25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melo</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Macedo-Souza</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Figueiredo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Muotri</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Coux</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Armas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Calcaterra</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Kitajima</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>Overexpression of <italic>KLC2</italic> due to a homozygous deletion
in the non-coding region causes SPOAN syndrome</article-title>
<source/>Hum Mol Genet
          <volume>24</volume>
<fpage>6877</fpage>
<lpage>6885</lpage>
<pub-id pub-id-type="pmid">26385635</pub-id>
</element-citation>
</ref>
<ref id="B26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Beetz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pessoa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Graciani</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Mitne</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hubert</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<year>2007a</year>
<article-title>A multi-exonic SPG4 duplication underlies sex-dependent penetrance of
hereditary spastic paraplegia in a large Brazilian pedigree</article-title>
<source/>Eur J Hum Genet
          <volume>15</volume>
<fpage>1276</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="pmid">17895902</pub-id>
</element-citation>
</ref>
<ref id="B27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Ramos</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Pimenta</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Luz</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Gonzales</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2007b</year>
<article-title>A mutation in human VAP-B—MSP domain, present in ALS patients, affects
the interaction with other cellular proteins</article-title>
<source/>Protein Expr Purif
          <volume>55</volume>
<fpage>139</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">17540579</pub-id>
</element-citation>
</ref>
<ref id="B28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Machado-Costa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marchetto</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bengtson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Joazeiro</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Tsuda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bellen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2011</year>
<article-title>Downregulation of VAPB expression in motor neurons derived from
induced pluripotent stem cells of ALS8 patients</article-title>
<source/>Hum Mol Genet
          <volume>20</volume>
<fpage>3642</fpage>
<lpage>3652</lpage>
<pub-id pub-id-type="pmid">21685205</pub-id>
</element-citation>
</ref>
<ref id="B29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monaco</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Bertelson</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Liechti-Gallati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kunkel</surname>
<given-names>LM</given-names>
</name>
</person-group>
<year>1988</year>
<article-title>An explanation for the phenotypic differences between patients bearing
partial deletions of the DMD locus</article-title>
<source/>Genomics
          <volume>2</volume>
<fpage>90</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">3384440</pub-id>
</element-citation>
</ref>
<ref id="B30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Sertie</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>The seventh form of autosomal recessive limb-girdle muscular dystrophy
is mapped to 17q11-12</article-title>
<source/>Am J Hum Genet
          <volume>61</volume>
<fpage>151</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">9245996</pub-id>
</element-citation>
</ref>
<ref id="B31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Wiltshire</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Faulkner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nilforoushan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>OT</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<year>2000</year>
<article-title>Limb-girdle muscular dystrophy type 2G is caused by mutations in the
gene encoding the sarcomeric protein telethonin</article-title>
<source/>Nat Genet
          <volume>24</volume>
<fpage>163</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">10655062</pub-id>
</element-citation>
</ref>
<ref id="B32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>OT</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Genotype-phenotype correlations in 35 Brazilian families with
sarcoglycanopathies including the description of three novel
mutations</article-title>
<source/>J Med Genet
          <volume>40</volume>
<fpage>E12</fpage>
<lpage>E12</lpage>
<pub-id pub-id-type="pmid">12566530</pub-id>
</element-citation>
</ref>
<ref id="B33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Moncivais</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Caplan</surname>
<given-names>AI</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Mesenchymal stem cells: Environmentally responsive therapeutics for
regenerative medicine</article-title>
<source/>Exp Mol Med
          <volume>45</volume>
<fpage>e54</fpage>
<lpage>e54</lpage>
<pub-id pub-id-type="pmid">24232253</pub-id>
</element-citation>
</ref>
<ref id="B34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nigro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>de Sa Moreira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Piluso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Belsito</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Politano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Puca</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1996</year>
<article-title>Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused
by a mutation in the delta-sarcoglycan gene</article-title>
<source/>Nat Genet
          <volume>14</volume>
<fpage>195</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">8841194</pub-id>
</element-citation>
</ref>
<ref id="B35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Silva</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2004a</year>
<article-title>A novel locus for late onset amyotrophic lateral sclerosis/motor
neurone disease variant at 20q13</article-title>
<source/>J Med Genet
          <volume>41</volume>
<fpage>315</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="pmid">15060112</pub-id>
</element-citation>
</ref>
<ref id="B36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mitne</surname>
<given-names>M</given-names>
<suffix>Neto</suffix>
</name>
<name>
<surname>Silva</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Richieri-Costa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gillingwater</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>2004b</year>
<article-title>A mutation in the vesicle-trafficking protein VAPB causes late-onset
spinal muscular atrophy and amyotrophic lateral sclerosis</article-title>
<source/>Am J Hum Genet
          <volume>75</volume>
<fpage>822</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="pmid">15372378</pub-id>
</element-citation>
</ref>
<ref id="B37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Al-Chalabi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in
the Brazilian population</article-title>
<source/>Hum Genet
          <volume>118</volume>
<fpage>499</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="pmid">16187141</pub-id>
</element-citation>
</ref>
<ref id="B38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nitahara-Kasahara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hayashita-Kinoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohshima-Hosoyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wada-Maeda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Long-term engraftment of multipotent mesenchymal stromal cells that
differentiate to form myogenic cells in dogs with Duchenne muscular
dystrophy</article-title>
<source/>Mol Ther
          <volume>20</volume>
<fpage>168</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">21934652</pub-id>
</element-citation>
</ref>
<ref id="B39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1994</year>
<article-title>Half the dystrophin gene is apparently enough for a mild clinical
course: Confirmation of its potential use for gene therapy</article-title>
<source/>Hum Mol Genet
          <volume>3</volume>
<fpage>919</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="pmid">7951237</pub-id>
</element-citation>
</ref>
<ref id="B40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bashir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Vasquez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iughetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Keers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<year>1995</year>
<article-title>Confirmation of the 2p locus for the mild autosomal recessive
limb-girdle muscular dystrophy gene (LGMD2B) in three families allows refinement
of the candidate region</article-title>
<source/>Genomics
          <volume>27</volume>
<fpage>192</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="pmid">7665169</pub-id>
</element-citation>
</ref>
<ref id="B41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1996</year>
<article-title>Linkage analysis in autosomal recessive limb-girdle muscular dystrophy
(AR LGMD) maps a sixth form to 5q33-34 (LGMD2F) and indicates that there is at
least one more subtype of AR LGMD</article-title>
<source/>Hum Mol Genet
          <volume>5</volume>
<fpage>815</fpage>
<lpage>820</lpage>
<pub-id pub-id-type="pmid">8776597</pub-id>
</element-citation>
</ref>
<ref id="B42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Janjoppi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rodini</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Araujo</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Cavalheiro</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>OK</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Contamination of mesenchymal stem-cells with fibroblasts accelerates
neurodegeneration in an experimental model of Parkinson's disease</article-title>
<source/>Stem Cell Rev
          <volume>7</volume>
<fpage>1006</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="pmid">21503590</pub-id>
</element-citation>
</ref>
<ref id="B43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tupler</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Facioscapulohumeral muscular dystrophy: More complex than it
appears</article-title>
<source/>Curr Mol Med
          <comment>[Epub ahead of print]</comment>
</element-citation>
</ref>
<ref id="B44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Broux</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Allamand</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fougerousse</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chiannilkulchai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bourg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brenguier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Devaud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pasturaud</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roudaut</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<year>1995</year>
<article-title>Mutations in the proteolytic enzyme calpain 3 cause limb-girdle
muscular dystrophy type 2A</article-title>
<source/>Cell
          <volume>81</volume>
<fpage>27</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">7720071</pub-id>
</element-citation>
</ref>
<ref id="B45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Roudaut</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saenz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pogue</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Beley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cobo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>de Diego</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<year>1999</year>
<article-title>Calpainopathy- A survey of mutations and polymorphisms</article-title>
<source/>Am J Hum Genet
          <volume>64</volume>
<fpage>1524</fpage>
<lpage>1540</lpage>
<pub-id pub-id-type="pmid">10330340</pub-id>
</element-citation>
</ref>
<ref id="B46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Froehner</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2000</year>
<article-title>Brazilian family with pure autosomal dominant spastic paraplegia maps
to 8q: Analysis of muscle beta 1 syntrophin</article-title>
<source/>Am J Med Genet
          <volume>92</volume>
<fpage>122</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">10797436</pub-id>
</element-citation>
</ref>
<ref id="B47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Larcher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dubreil</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deschamps</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Le Guiner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jouvion</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lieubeau</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Carlus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fornasari</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<year>2011</year>
<article-title>Systemic delivery of allogenic muscle stem cells induces long-term
muscle repair and clinical efficacy in Duchenne muscular dystrophy
dogs</article-title>
<source/>Am J Pathol
          <volume>179</volume>
<fpage>2501</fpage>
<lpage>2518</lpage>
<pub-id pub-id-type="pmid">21924229</pub-id>
</element-citation>
</ref>
<ref id="B48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampaolesi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>D'Antona</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Granger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tonlorenzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Innocenzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mognol</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thibaud</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Galvez</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Barthelemy</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<year>2006</year>
<article-title>Mesoangioblast stem cells ameliorate muscle function in dystrophic
dogs</article-title>
<source/>Nature
          <volume>444</volume>
<fpage>574</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="pmid">17108972</pub-id>
</element-citation>
</ref>
<ref id="B49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scionti</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Govi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arashiro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vercelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Berardinelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Angelini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Large-scale population analysis challenges the current criteria for
the molecular diagnosis of fascioscapulohumeral muscular dystrophy</article-title>
<source/>Am J Hum Genet
          <volume>90</volume>
<fpage>628</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="pmid">22482803</pub-id>
</element-citation>
</ref>
<ref id="B50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Fogaca</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Cerqueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Muotri</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2008a</year>
<article-title>Mesenchymal stem cells from umbilical cord: Do not discard the
cord!</article-title>
<source/>Neuromuscul Disord
          <volume>18</volume>
<fpage>17</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">18155523</pub-id>
</element-citation>
</ref>
<ref id="B51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Fogaca</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Cerqueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Muotri</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2008b</year>
<article-title>Multipotent stem cells from umbilical cord: Cord is richer than
blood!</article-title>
<source/>Stem Cells
          <volume>26</volume>
<fpage>146</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="pmid">17932423</pub-id>
</element-citation>
</ref>
<ref id="B52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Muotri</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Verjovski-Almeida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Gene expression profile of mesenchymal stem cells from paired
umbilical cord units: Cord is different from blood</article-title>
<source/>Stem Cell Rev
          <volume>5</volume>
<fpage>387</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">20058202</pub-id>
</element-citation>
</ref>
<ref id="B53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharp</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Kornegay</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Van Camp</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Herbstreith</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Secore</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Kettle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Constantinou</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Dykstra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Roses</surname>
<given-names>AD</given-names>
</name>
<etal></etal>
</person-group>
<year>1992</year>
<article-title>An error in dystrophin mRNA processing in golden retriever muscular
dystrophy, an animal homologue of Duchenne muscular dystrophy</article-title>
<source/>Genomics
          <volume>13</volume>
<fpage>115</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">1577476</pub-id>
</element-citation>
</ref>
<ref id="B54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Tidball</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Somer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>Absence of calpain 3 in a form of limb-girdle muscular dystrophy
(LGMD2A)</article-title>
<source/>J Neurol Sci
          <volume>146</volume>
<fpage>173</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">9077514</pub-id>
</element-citation>
</ref>
<ref id="B55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rocco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cambi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hobson</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Passos Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2002a</year>
<article-title>Further evidence for a fourth gene causing X-linked pure spastic
paraplegia</article-title>
<source/>Am J Med Genet
          <volume>111</volume>
<fpage>152</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">12210342</pub-id>
</element-citation>
</ref>
<ref id="B56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rocco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Hazan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2002b</year>
<article-title>Autosomal dominant (AD) pure spastic paraplegia (HSP) linked to locus
SPG4 affects almost exclusively males in a large pedigree</article-title>
<source/>J Med Genet
          <volume>39</volume>
<fpage>e77</fpage>
<lpage>e77</lpage>
<pub-id pub-id-type="pmid">12471215</pub-id>
</element-citation>
</ref>
<ref id="B57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Paula</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Calpainopathy: How broad is the spectrum of clinical
variability?</article-title>
<source/>J Mol Neurosci
          <volume>21</volume>
<fpage>233</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="pmid">14645990</pub-id>
</element-citation>
</ref>
<ref id="B58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2004</year>
<article-title>A new form of autosomal dominant limb-girdle muscular dystrophy
(LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome
4p21</article-title>
<source/>Eur J Hum Genet
          <volume>12</volume>
<fpage>1033</fpage>
<lpage>1040</lpage>
<pub-id pub-id-type="pmid">15367920</pub-id>
</element-citation>
</ref>
<ref id="B59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takata</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Speck Martins</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Da Silva</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>A</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Lima</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2004</year>
<article-title>A new locus for recessive distal spinal muscular atrophy at
Xq13.1-q21</article-title>
<source/>J Med Genet
          <volume>41</volume>
<fpage>224</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">14985388</pub-id>
</element-citation>
</ref>
<ref id="B60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Induction of pluripotent stem cells from mouse embryonic and adult
fibroblast cultures by defined factors</article-title>
<source/>Cell
          <volume>126</volume>
<fpage>663</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="pmid">16904174</pub-id>
</element-citation>
</ref>
<ref id="B61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teuling</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haasdijk</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Demmers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steinmetz</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Akhmanova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jaarsma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hoogenraad</surname>
<given-names>CC</given-names>
</name>
</person-group>
<year>2007</year>
<article-title>Motor neuron disease-associated mutant vesicle-associated membrane
protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic
reticulum-derived tubular aggregates</article-title>
<source/>J Neurosci
          <volume>27</volume>
<fpage>9801</fpage>
<lpage>9815</lpage>
<pub-id pub-id-type="pmid">17804640</pub-id>
</element-citation>
</ref>
<ref id="B62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonini</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cerqueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matioli</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2004</year>
<article-title>Asymptomatic carriers and gender differences in facioscapulohumeral
muscular dystrophy (FSHD)</article-title>
<source/>Neuromuscul Disord
          <volume>14</volume>
<fpage>33</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">14659410</pub-id>
</element-citation>
</ref>
<ref id="B63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>I</given-names>
<suffix>Filho</suffix>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hsi</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1990</year>
<article-title>Dystrophin immunostaining in muscles from patients with different
types of muscular dystrophy: A Brazilian study</article-title>
<source/>J Neurol Sci
          <volume>98</volume>
<fpage>221</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="pmid">1700808</pub-id>
</element-citation>
</ref>
<ref id="B64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>I</given-names>
<suffix>Filho</suffix>
</name>
<name>
<surname>Rapaport</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zubrzycka-Gaarn</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Bulman</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1991a</year>
<article-title>Screening of male patients with autosomal recessive Duchenne dystrophy
through dystrophin and DNA studies</article-title>
<source/>Am J Med Genet
          <volume>39</volume>
<fpage>38</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">1867262</pub-id>
</element-citation>
</ref>
<ref id="B65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tsanaclis</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1991b</year>
<article-title>Dystrophin immunofluorescence pattern in manifesting and asymptomatic
carriers of Duchenne's and Becker muscular dystrophies of different
ages</article-title>
<source/>Neuromuscul Disord
          <volume>1</volume>
<fpage>177</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="pmid">1822792</pub-id>
</element-citation>
</ref>
<ref id="B66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zubrzycka-Gaarn</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>I</given-names>
<suffix>Filho</suffix>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1991c</year>
<article-title>Immunofluorescence dystrophin study in Duchenne dystrophy through the
concomitant use of two antibodies directed against the carboxy-terminal and the
amino-terminal region of the protein</article-title>
<source/>J Neurol Sci
          <volume>101</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">1709683</pub-id>
</element-citation>
</ref>
<ref id="B67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1993</year>
<article-title>Is the maintainance of the C-terminus domain of dystrophin enough to
ensure a milder Becker muscular dystrophy phenotype?</article-title>
<source/>Hum Mol Genet
          <volume>2</volume>
<fpage>39</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">8490621</pub-id>
</element-citation>
</ref>
<ref id="B68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1995a</year>
<article-title>Absence of correlation between utrophin localization and quantity and
the clinical severity in Duchenne/Becker dystrophies</article-title>
<source/>Am J Med Genet
          <volume>58</volume>
<fpage>305</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="pmid">8533838</pub-id>
</element-citation>
</ref>
<ref id="B69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1995b</year>
<article-title>Is dystrophin always altered in Becker muscular dystrophy
patients?</article-title>
<source/>J Neurol Sci
          <volume>131</volume>
<fpage>99</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">7561956</pub-id>
</element-citation>
</ref>
<ref id="B70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Canovas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Bonnemann</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<year>1996</year>
<article-title>The sarcoglycan complex in the six autosomal recessive limb-girdle
muscular dystrophies</article-title>
<source/>Hum Mol Genet
          <volume>5</volume>
<fpage>1963</fpage>
<lpage>1969</lpage>
<pub-id pub-id-type="pmid">8968750</pub-id>
</element-citation>
</ref>
<ref id="B71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>1999</year>
<article-title>Sarcoglycanopathies are responsible for 68% of severe autosomal
recessive limb-girdle muscular dystrophy in the Brazilian
population</article-title>
<source/>J Neurol Sci
          <volume>164</volume>
<fpage>44</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">10385046</pub-id>
</element-citation>
</ref>
<ref id="B72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>OT</given-names>
</name>
<name>
<surname>Faulkner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beggs</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Carpen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Zanoteli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gurgel-Gianneti</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>2002</year>
<article-title>Telethonin protein expression in neuromuscular
disorders</article-title>
<source/>Biochim Biophys Acta
          <volume>1588</volume>
<fpage>33</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">12379311</pub-id>
</element-citation>
</ref>
<ref id="B73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jimenez-Mallebrera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Talim</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>LU</given-names>
</name>
<name>
<surname>Ledeuil</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Abbs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brockington</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2005</year>
<article-title>Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient
congenital muscular dystrophy: A collective experience of five international
centers</article-title>
<source/>Neuromuscul Disord
          <volume>15</volume>
<fpage>588</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="pmid">16084089</pub-id>
</element-citation>
</ref>
<ref id="B74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Feitosa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ayub-Guerrieri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Canovas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RCM</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Mild course in atypical Duchenne muscular dystrophy patients is not
caused by utrophin overexpression</article-title>
<source/>Neuromuscul. Disord
          <volume>26</volume>
<fpage>197</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">26851826</pub-id>
</element-citation>
</ref>
<ref id="B75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valadares</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Assoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pellati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Corselli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>Human adipose tissue derived pericytes increase life span in Utrn
(tm1Ked) Dmd (mdx) /J mice</article-title>
<source/>Stem Cell Rev
          <volume>10</volume>
<fpage>830</fpage>
<lpage>840</lpage>
<pub-id pub-id-type="pmid">24943487</pub-id>
</element-citation>
</ref>
<ref id="B76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valdmanis</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>A</given-names>
</name>
<name>
<surname>MacLeod</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dion</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Drapeau</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<year>2007</year>
<article-title>Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary
spastic paraplegia</article-title>
<source/>Am J Hum Genet
          <volume>80</volume>
<fpage>152</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="pmid">17160902</pub-id>
</element-citation>
</ref>
<ref id="B77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valle</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Faulkner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Antoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pacchioni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pallavicini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pandolfo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tiso</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Toppo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trevisan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lanfranchi</surname>
<given-names>G</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>Telethonin, a novel sarcomeric protein of heart and skeletal
muscle</article-title>
<source/>FEBS Lett
          <volume>415</volume>
<fpage>163</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="pmid">9350988</pub-id>
</element-citation>
</ref>
<ref id="B78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Brandalise</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Moraes</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brum</surname>
<given-names>PC</given-names>
</name>
<etal></etal>
</person-group>
<year>2008</year>
<article-title>SJL dystrophic mice express a significant amount of human muscle
proteins following systemic delivery of human adipose-derived stromal cells
without immunosuppression</article-title>
<source/>Stem Cells
          <volume>26</volume>
<fpage>2391</fpage>
<lpage>2398</lpage>
<pub-id pub-id-type="pmid">18583542</pub-id>
</element-citation>
</ref>
<ref id="B79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Human multipotent mesenchymal stromal cells from distinct sources show
different in vivo potential to differentiate into muscle cells when injected in
dystrophic mice</article-title>
<source/>Stem Cell Rev
          <volume>6</volume>
<fpage>560</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">20821076</pub-id>
</element-citation>
</ref>
<ref id="B80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Valadares</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>CR</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Brandalise</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Assoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Landini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Human adipose-derived mesenchymal stromal cells injected systemically
into GRMD dogs without immunosuppression are able to reach the host muscle and
express human dystrophin</article-title>
<source/>Cell Transplant
          <volume>21</volume>
<fpage>1407</fpage>
<lpage>1417</lpage>
<pub-id pub-id-type="pmid">23168016</pub-id>
</element-citation>
</ref>
<ref id="B81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Naslavsky</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Licinio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kitajima</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Gal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cavacana</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>A defect in the RNA-processing protein HNRPDL causes limb-girdle
muscular dystrophy 1G (LGMD1G)</article-title>
<source/>Hum Mol Genet
          <volume>23</volume>
<fpage>4103</fpage>
<lpage>4110</lpage>
<pub-id pub-id-type="pmid">24647604</pub-id>
</element-citation>
</ref>
<ref id="B82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Elvers</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Eran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Karlsson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Verjovski-Almeida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lindblad-Toh</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>Jagged 1 rescues the Duchenne Muscular Dystrophy
phenotype</article-title>
<source/>Cell
          <volume>163</volume>
<fpage>1204</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">26582133</pub-id>
</element-citation>
</ref>
<ref id="B83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>LU</given-names>
</name>
<name>
<surname>Gollop</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Naccache</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zanoteli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2004</year>
<article-title>Protein and DNA analysis for the prenatal diagnosis of
alpha2-laminin-deficient congenital muscular dystrophy</article-title>
<source/>Diagn Mol Pathol
          <volume>13</volume>
<fpage>167</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="pmid">15322429</pub-id>
</element-citation>
</ref>
<ref id="B84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>LU</given-names>
</name>
<name>
<surname>Velloso</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Fogaca</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>de Paula</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2008</year>
<article-title>Muscle protein alterations in LGMD2I patients with different mutations
in the Fukutin-related protein gene</article-title>
<source/>J Histochem Cytochem
          <volume>56</volume>
<fpage>995</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="pmid">18645206</pub-id>
</element-citation>
</ref>
<ref id="B85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>1990</year>
<article-title>Glycoprotein complex anchoring dystrophin to
sarcolemma</article-title>
<source/>J Biochem
          <volume>108</volume>
<fpage>748</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="pmid">2081733</pub-id>
</element-citation>
</ref>
<ref id="B86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Global voices of science. When science is not enough: Fighting genetic
disease in Brazil</article-title>
<source/>Science
          <volume>308</volume>
<fpage>55</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">15802588</pub-id>
</element-citation>
</ref>
<ref id="B87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Response to: Milder course in Duchenne patients with nonsense
mutations and no muscle dystrophin</article-title>
<source/>Neuromuscul Disord
          <volume>25</volume>
<fpage>444</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">25777492</pub-id>
</element-citation>
</ref>
<ref id="B88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vianna-Morgante</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Diament</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<year>1981</year>
<article-title>Translocation (X;6) in a female with Duchenne muscular dystrophy:
Implications for the localisation of the DMD locus</article-title>
<source/>J Med Genet
          <volume>18</volume>
<fpage>442</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="pmid">7334502</pub-id>
</element-citation>
</ref>
<ref id="B89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos-Bueno</surname>
<given-names>MR</given-names>
</name>
</person-group>
<year>2000</year>
<article-title>Limb-girdle muscular dystrophy: One gene with different phenotypes,
one phenotype with different genes</article-title>
<source/>Curr Opin Neurol
          <volume>13</volume>
<fpage>511</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">11073356</pub-id>
</element-citation>
</ref>
<ref id="B90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Paula</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Starling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>The 10 autosomal recessive limb-girdle muscular
dystrophies</article-title>
<source/>Neuromuscul Disord
          <volume>13</volume>
<fpage>532</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="pmid">12921790</pub-id>
</element-citation>
</ref>
<ref id="B91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello R de</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cerqueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Assessing pathogenicity for novel mutation/sequence variants: The
value of healthy older individuals</article-title>
<source/>Neuromolecular Med
          <volume>14</volume>
<fpage>281</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="pmid">22707356</pub-id>
</element-citation>
</ref>
<ref id="B92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavanello</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cerqueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Milder course in Duchenne patients with nonsense mutations and no
muscle dystrophin</article-title>
<source/>Neuromuscul Disord
          <volume>24</volume>
<fpage>986</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="pmid">25047667</pub-id>
</element-citation>
</ref>
<ref id="B93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pelatti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Landini</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>Long term follow-up of GRMD dogs transplanted with human adipose
derived stem cells</article-title>
<source/>Neuromuscul Disord
          <volume>25</volume>
<issue>suppl 2</issue>
<fpage>S290</fpage>
<lpage>S290</lpage>
</element-citation>
</ref>
<ref id="B94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zucconi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Valadares</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Secco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jazedje</surname>
<given-names>T</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Vainzof</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zatz</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Ringo: Discordance between the molecular and clinical manifestation in
a golden retriever muscular dystrophy dog</article-title>
<source/>Neuromuscul Disord
          <volume>20</volume>
<fpage>64</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">19944604</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>